Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label doravirine/islatravir dose-reduction continuation study in adults with HIV-1
MOH_2023-04-03_012498Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of doravirine and islatravir in Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Started Mar 2023; status: active, not recruiting.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on MOH_2023-04-03_012498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-03_012498.